Research Journal of Pharmacy and Technology
SCOPUS
  • Year: 2023
  • Volume: 16
  • Issue: 1

Antinociceptive investigations of rubiadin in chronic pain induced by freund’s adjuvant in mice

  • Author:
  • Prakash M. Somade1, Pramod Anil Patil2,*, Suraj N. Mali3, Pratibha S. Gavarkar4, Rohan Sharadanand Phatak1, Rajashree S. Chavan5, Atul R. Chopade2
  • Total Page Count: 4
  • Page Number: 31 to 34

1Krishna Institute of Medical Science "Deemed to be University", Karad - 415539, Maharashtra

2Rajarambapu College of Pharmacy, Kasegaon, District - Sangli, Maharashtra, 415404, India

3Department of Pharmaceutical Sciences and Technology, Birla Institute of TechnologyMesra, Ranchi, (Jharkhand) 835215India

4Dept. of Pharmaceutical Chemistry, Anandi Pharmacy College, Kalambe tarf Kale, Tal - Karveer, Dist- Kolhapur, 416205

5Principal, Seth Govind Raghunath Sable College of Pharmacy, Saswad, Dist - Pune, Tal - Purandar, 412301

*Corresponding Author E-mail: prithvirajpatil87@gmail.com

Online Published on 10 October, 2023.

Abstract

Main aim of study is to investigate the Rubiadin effects in mice model of chronic inflammation and pain. Complete Freund’s adjuvant (CFA) inflammatory model was used for investigation of chronic hypersensitivity. Prior CFA inflammation, Von Frey filaments and acetone induced cold sensitivity test was used to evaluate hypersensitivity, respectively. The paw edema was measured using digital plethysmometer. Intraperitoneally administered Rubiadin (100 and 200mg/kg) prior testing reduced CFA induced mechanical hypersensitivity. Rubiadin reduces evoked acetone cold hypersensitivity. Compared with vehicle, Rubiadin reduces paw edema too. Rubiadin reduced mechanical hypersensitivity significantly when administered two times a day from first to fifth day and from ninth to tenth day. In conclusion study revealed Rubiadin anti-nociceptive activity in chronic pain and also might be potential for effective management of pain.

Keywords

Rubiadin, CFA, Antinociceptive activity